#AstraZeneca-CICC
LightNews LightNews
newsen.bsky.social
YolTech Therapeutics Secures $45 Million in Series B Funding to Advance Gene-Editing Therapies#China#Shanghai#YolTech_Therapeutics#gene-editing#AstraZeneca-CICC
YolTech Therapeutics Secures $45 Million in Series B Funding to Advance Gene-Editing Therapies
YolTech Therapeutics has successfully raised $45 million in Series B funding, led by AstraZeneca-CICC, to progress its innovative gene-editing therapies.
third-news.com
September 11, 2025 at 12:27 PM
endpts.com
YolTech raised $45M to advance its CRISPR therapies, aiming for its first Phase 3 trial at a time when US rivals are scaling back and investors are eyeing China’s biotech scene.
Exclusive: Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 study
YolTech Therapeutics raises $44.5M Series B for CRISPR therapies, led by AstraZeneca-CICC fund. Company has 4 therapies in clinical trials, plans Phase 3 for ATTR treatment.
endpoints.news
September 10, 2025 at 8:51 PM
scienceboss.bsky.social
Chinese #CRISPR company YolTech Therapeutics has raised a $45M series B as it plans for its first Phase 3 study in ATTR, the same genetic disease that US-based Intellia recently began a pair of Phase 3 studies in. Read more in my exclusive for
@endpts.com: endpoints.news/chinese-cris...
Exclusive: Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 study
YolTech Therapeutics raises $44.5M Series B for CRISPR therapies, led by AstraZeneca-CICC fund. Company has 4 therapies in clinical trials, plans Phase 3 for ATTR treatment.
endpoints.news
September 10, 2025 at 3:33 PM
blueresearch.bsky.social
AstraZeneca initiated with bullish view at CICC
Reported Monday, Aug 24 - 4:30am EDT (TheFly subscription required to read more.)
thefly.com
August 24, 2026 at 8:30 AM
blueresearch.bsky.social
AstraZeneca initiated with bullish view at CICC
Reported Sunday, Aug 23 - 10:11am EDT (TheFly subscription required to read more.)
thefly.com
August 23, 2026 at 2:20 PM
longtail-news.bsky.social
Feed: "Endpoints News"
By: Ryan Cross on Wednesday, September 10, 2025
Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 study
YolTech Therapeutics raises $44.5M Series B for CRISPR therapies, led by AstraZeneca-CICC fund. Company has 4 therapies in clinical trials, plans Phase 3 for ATTR treatment.
endpoints.news
September 11, 2025 at 11:41 AM
l2plabs.bsky.social
YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICC
SHANGHAI, Sept. 11, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately $45 million Series B financing led by the AstraZeneca-CICC healthcare investment fund. The proceeds...
dlvr.it
September 11, 2025 at 12:35 PM